ARTICLE | Clinical News
ATB-346: Development resumed
March 23, 2015 7:00 AM UTC
Antibe resumed development of ATB-346 following collection and review of data from a double-blind, placebo-controlled, Canadian Phase I trial evaluating single and multiple ascending doses of oral ATB...